SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

India Ratings affirms Nectar Lifesciences’ long-term issuer rating at ‘A-’

26 Apr 2013 Evaluate

India Ratings & Research has affirmed Nectar Lifesciences’ long-term issuer rating at ‘A-’ with stable outlook.

The affirmation reflects the rating agency’s opinion that the company’s financial leverage (adjusted debt net cash/EBITDA) will see a sustained improvement over the medium term after deteriorating to 4.1x in FY12 (financial year ended March) from 3.3x in FY11.

Nectar Lifesciences is a $200 million pharmaceutical organization. The company offers a range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms.

Nectar Lifesciences Share Price

12.66 0.25 (2.01%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×